Spyre Therapeutics Statistics
Total Valuation
SYRE has a market cap or net worth of $8.58 billion. The enterprise value is $7.83 billion.
| Market Cap | 8.58B |
| Enterprise Value | 7.83B |
Important Dates
The next estimated earnings date is Tuesday, August 4, 2026, after market close.
| Earnings Date | Aug 4, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
SYRE has 86.84 million shares outstanding. The number of shares has increased by 29.57% in one year.
| Current Share Class | 86.84M |
| Shares Outstanding | 86.84M |
| Shares Change (YoY) | +29.57% |
| Shares Change (QoQ) | +4.61% |
| Owned by Insiders (%) | 5.84% |
| Owned by Institutions (%) | 91.74% |
| Float | 80.98M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 15.12 |
| P/TBV Ratio | 16.65 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 8.97
| Current Ratio | 8.97 |
| Quick Ratio | 8.80 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -31.11% and return on invested capital (ROIC) is -26.19%.
| Return on Equity (ROE) | -31.11% |
| Return on Assets (ROA) | -22.65% |
| Return on Invested Capital (ROIC) | -26.19% |
| Return on Capital Employed (ROCE) | -35.60% |
| Weighted Average Cost of Capital (WACC) | 20.88% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.33M |
| Employee Count | 112 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +532.61% in the last 52 weeks. The beta is 3.02, so SYRE's price volatility has been higher than the market average.
| Beta (5Y) | 3.02 |
| 52-Week Price Change | +532.61% |
| 50-Day Moving Average | 79.16 |
| 200-Day Moving Average | 45.81 |
| Relative Strength Index (RSI) | 66.92 |
| Average Volume (20 Days) | 1,810,316 |
Short Selling Information
The latest short interest is 12.62 million, so 14.53% of the outstanding shares have been sold short.
| Short Interest | 12.62M |
| Short Previous Month | 12.63M |
| Short % of Shares Out | 14.53% |
| Short % of Float | 15.58% |
| Short Ratio (days to cover) | 11.85 |
Income Statement
| Revenue | n/a |
| Gross Profit | -171.65M |
| Operating Income | -241.64M |
| Pretax Income | -179.44M |
| Net Income | -148.70M |
| EBITDA | n/a |
| EBIT | -241.64M |
| Earnings Per Share (EPS) | -$2.17 |
Balance Sheet
The company has $741.47 million in cash and n/a in debt, with a net cash position of $741.47 million or $8.54 per share.
| Cash & Cash Equivalents | 741.47M |
| Total Debt | n/a |
| Net Cash | 741.47M |
| Net Cash Per Share | $8.54 |
| Equity (Book Value) | 670.81M |
| Book Value Per Share | 6.53 |
| Working Capital | 678.79M |
Cash Flow
| Operating Cash Flow | -185.63M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | n/a |
| Net Borrowing | n/a |
| Free Cash Flow | -185.63M |
| FCF Per Share | -$2.14 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
SYRE does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -29.57% |
| Shareholder Yield | -29.57% |
| Earnings Yield | -1.73% |
| FCF Yield | -2.16% |
Analyst Forecast
The average price target for SYRE is $100.47, which is 1.74% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $100.47 |
| Price Target Difference | 1.74% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 17 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on September 8, 2023. It was a reverse split with a ratio of 1:25.
| Last Split Date | Sep 8, 2023 |
| Split Type | Reverse |
| Split Ratio | 1:25 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |